Nothing Special   »   [go: up one dir, main page]

SG11202111993SA - Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors - Google Patents

Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors

Info

Publication number
SG11202111993SA
SG11202111993SA SG11202111993SA SG11202111993SA SG11202111993SA SG 11202111993S A SG11202111993S A SG 11202111993SA SG 11202111993S A SG11202111993S A SG 11202111993SA SG 11202111993S A SG11202111993S A SG 11202111993SA SG 11202111993S A SG11202111993S A SG 11202111993SA
Authority
SG
Singapore
Prior art keywords
inhibitors
intermediates
preparing
preparation
xpo1
Prior art date
Application number
SG11202111993SA
Inventor
Brian Clinton Austad
David G Roe
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of SG11202111993SA publication Critical patent/SG11202111993SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202111993SA 2019-05-01 2020-05-01 Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors SG11202111993SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841649P 2019-05-01 2019-05-01
PCT/US2020/031124 WO2020223678A1 (en) 2019-05-01 2020-05-01 Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors

Publications (1)

Publication Number Publication Date
SG11202111993SA true SG11202111993SA (en) 2021-11-29

Family

ID=70802955

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111993SA SG11202111993SA (en) 2019-05-01 2020-05-01 Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors

Country Status (14)

Country Link
US (1) US20220242832A1 (en)
EP (1) EP3962898A1 (en)
JP (1) JP2022531576A (en)
KR (1) KR20220004142A (en)
CN (1) CN114040909A (en)
AU (1) AU2020266170A1 (en)
BR (1) BR112021021706A2 (en)
CA (1) CA3135712A1 (en)
CR (1) CR20210590A (en)
IL (1) IL287673A (en)
MA (1) MA55808A (en)
MX (1) MX2021013211A (en)
SG (1) SG11202111993SA (en)
WO (1) WO2020223678A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112679477B (en) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 Preparation method of celecoxib and intermediate thereof
CN116514773A (en) * 2023-04-24 2023-08-01 重庆汉佩生物科技有限公司 Verdinexor (KPT-335) and synthesis method of hydrochloride thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200088518A (en) 2011-07-29 2020-07-22 카리오팜 쎄라퓨틱스, 인코포레이티드 Hydrazide containing nuclear transport modulators and uses thereof
PT3404027T (en) * 2012-05-09 2020-03-30 Biogen Ma Inc Nuclear transport modulators and uses thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10519139B2 (en) 2014-08-15 2019-12-31 Karyopharm Therapeutics Inc. Polymorphs of Selinexor
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018129227A1 (en) * 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
US20220242832A1 (en) 2022-08-04
BR112021021706A2 (en) 2022-04-19
EP3962898A1 (en) 2022-03-09
MX2021013211A (en) 2022-03-11
JP2022531576A (en) 2022-07-07
IL287673A (en) 2021-12-01
WO2020223678A1 (en) 2020-11-05
KR20220004142A (en) 2022-01-11
CN114040909A (en) 2022-02-11
CR20210590A (en) 2022-03-11
MA55808A (en) 2022-03-09
CA3135712A1 (en) 2020-11-05
AU2020266170A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
IL281082A (en) Compositions of cxcr4 inhibitors and methods of preparation and use
IL281152A (en) Process for preparing jak inhibitors and intermediates thereof
IL287673A (en) Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors
ZA202101214B (en) Process and intermediates for the preparation of bilastine
EP3376870A4 (en) Process for the preparation of kinase inhibitors and intermediates thereof
ZA202003590B (en) Process for the preparation of opicapone and intermediates thereof
IL290185A (en) Solid state forms of risdiplam and process for preparation thereof
IL264854A (en) Spt5 inhibitors and methods of use thereof
IL272837A (en) Process for the preparation of tubulysins and intermediates thereof
ZA202201324B (en) Abrasive article and method of forming
IL283281A (en) Formulation of contrast media and process of preparation thereof
GB2589398B (en) Compounds and methods of use
EP3864011A4 (en) Process for preparation of eribulin and intermediates thereof
HUE058259T2 (en) Process for the preparation of lubiprostone and intermediates thereof
PL3737685T3 (en) Process for the preparation of crisaborole and its intermediates
ZA202107053B (en) Novel process for the preparation of filgotinib and intermediates thereof
IL290169A (en) Process and intermediates for the preparation of pyroxasulfone
ZA202107810B (en) Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof
IL278549B1 (en) Intermediates and processes for the preparation of linagliptin and its salts
PL3969459T3 (en) Process and intermediates for the preparation of eldecalcitol
RS65238B1 (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
HUP2100077A1 (en) Process for the preparation of avapritinib and intermediates for the process
EP4051681A4 (en) Process for the preparation of tofacitinib and intermediates thereof
GB201911627D0 (en) Polymorph of venetoclax and method for preparing the polymorph
GB201908573D0 (en) Compounds and methods of use